Endo International PLC (NASDAQ:ENDP) EVP Matthew Joseph Maletta acquired 3,000 shares of the firm’s stock in a transaction that occurred on Tuesday, August 15th. The stock was purchased at an average cost of $8.02 per share, with a total value of $24,060.00. Following the purchase, the executive vice president now directly owns 6,984 shares in the company, valued at approximately $56,011.68. The purchase was disclosed in a document filed with the SEC, which is accessible through this hyperlink.

Endo International PLC (NASDAQ ENDP) traded up 6.82% on Tuesday, hitting $8.14. 9,968,740 shares of the stock were exchanged. The stock’s market capitalization is $1.82 billion. Endo International PLC has a one year low of $7.41 and a one year high of $24.93. The company has a 50 day moving average of $10.81 and a 200 day moving average of $11.52.

Endo International PLC (NASDAQ:ENDP) last announced its earnings results on Tuesday, August 8th. The company reported $0.93 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.74 by $0.19. Endo International PLC had a negative net margin of 126.93% and a positive return on equity of 37.58%. The business had revenue of $875.73 million during the quarter, compared to analysts’ expectations of $832.66 million. During the same quarter in the prior year, the company posted $0.86 earnings per share. The firm’s revenue was down 4.9% on a year-over-year basis. On average, equities research analysts forecast that Endo International PLC will post $3.52 earnings per share for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: “Matthew Joseph Maletta Buys 3,000 Shares of Endo International PLC (ENDP) Stock” was first reported by American Banking News and is owned by of American Banking News. If you are accessing this story on another domain, it was illegally stolen and reposted in violation of US and international trademark and copyright laws. The legal version of this story can be read at https://www.americanbankingnews.com/2017/08/15/matthew-joseph-maletta-buys-3000-shares-of-endo-international-plc-endp-stock.html.

A number of hedge funds and other institutional investors have recently made changes to their positions in ENDP. OppenheimerFunds Inc. boosted its position in shares of Endo International PLC by 182.9% in the first quarter. OppenheimerFunds Inc. now owns 2,873,153 shares of the company’s stock valued at $32,065,000 after buying an additional 1,857,678 shares during the last quarter. Bank of New York Mellon Corp boosted its position in shares of Endo International PLC by 38.7% in the first quarter. Bank of New York Mellon Corp now owns 2,271,111 shares of the company’s stock valued at $25,345,000 after buying an additional 633,904 shares during the last quarter. First Quadrant L P CA acquired a new position in shares of Endo International PLC during the first quarter valued at approximately $24,556,000. Teachers Advisors LLC boosted its position in shares of Endo International PLC by 1.9% in the second quarter. Teachers Advisors LLC now owns 840,470 shares of the company’s stock valued at $9,388,000 after buying an additional 15,928 shares during the last quarter. Finally, TIAA CREF Investment Management LLC boosted its position in shares of Endo International PLC by 1.6% in the second quarter. TIAA CREF Investment Management LLC now owns 649,535 shares of the company’s stock valued at $7,255,000 after buying an additional 10,387 shares during the last quarter. Institutional investors and hedge funds own 92.27% of the company’s stock.

ENDP has been the subject of a number of recent analyst reports. Zacks Investment Research raised shares of Endo International PLC from a “sell” rating to a “hold” rating in a research note on Tuesday, May 2nd. ValuEngine lowered shares of Endo International PLC from a “buy” rating to a “hold” rating in a research note on Friday, June 2nd. Oppenheimer Holdings, Inc. reissued a “hold” rating on shares of Endo International PLC in a research note on Tuesday, August 8th. Deutsche Bank AG decreased their target price on shares of Endo International PLC from $18.00 to $15.00 and set a “buy” rating for the company in a research note on Friday, July 7th. Finally, BMO Capital Markets reissued a “hold” rating and set a $16.00 target price on shares of Endo International PLC in a research note on Wednesday, May 17th. Three equities research analysts have rated the stock with a sell rating, sixteen have given a hold rating and five have issued a buy rating to the company. The company currently has an average rating of “Hold” and an average price target of $14.75.

About Endo International PLC

Endo International PLC, formerly Endo Health Solutions Inc is a specialty healthcare solutions company focused on branded and generic pharmaceuticals, devices and services. The Company has a portfolio of branded pharmaceuticals that includes brands, such as Lidoderm, Opana ER, Voltaren Gel, Percocet, Frova, Supprelin LA, Vantas, Valstar and Fortesta Gel.

Receive News & Ratings for Endo International PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endo International PLC and related companies with MarketBeat.com's FREE daily email newsletter.